Table 3.

Data collection and assessment schedule.

Assessment Time Period	T1	T2			T3	T4
HCV Treatment Time point	Baseline Pre-Treatment	Start of HCV Treatment			Week 12 HCV Treatment	Week 24 HCV Treatment
CBCS-HCV Time point	Baseline Start CBCS	CBCS sessions 1–4	Session 5	CBCS sessions 6–10	Final CBCS session 10	3-month Post-CBCS
Study Feasibility
Ratio of screens/enrollees	X
RCT Study Design	X
Retention Rates	X	X	X	X	X	X
Study Visit Attendance	X		X		X	X
CBCS Session Attendance		X	X	X	X
Missing Data	X	X	X	X	X	X
Patient Acceptability		X	X	X	X
Protocol Fidelity
Therapist's Adherence		X	X	X	X
Therapist's Competence		X	X	X	X
Demographics/Clinical	X
Psychosocial Surveys
FACIT HRQOL	X		X		X	X
PSS Stress Severity	X		X		X	X
Depression	X		X		X	X
Anger	X		X		X	X
Anxiety	X		X		X	X
Fatigue	X		X		X	X
Sleep Disturbance	X		X		X	X
Sleep Impairment	X		X		X	X
Pain Intensity	X		X		X	X
Pain Interference	X		X		X	X
Medication Adherence
MEMS Caps				X	X	X
Pill Counts				X	X	X
Self-Report Adherence				X	X	X
Medical
Treatment Completion						X
Virological Response					X	X
Process Measures
Group Processes					X
MOCS	X				X	X
Treatment Self-Efficacy	X				X	X

T1: Baseline assessment after consent and screening.

T2: For participants in the CBCS-HCV condition, after CBCS session #5, immediately before starting HCV treatment. SC participants completed T2 immediately before starting HCV treatment.

T3: At HCV Treatment Week 12 for all study participants. Immediately following the last CBCS-HCV session for the CBCS-HCV participants.

T4: Three months post-intervention, at treatment week 24 for patients still on HCV treatment.